IGFBP-1 Antibody (33627) [Unconjugated]

Western blot shows 25 ng of Recombinant Human IGFBP-1 (Catalog # 871-B1), Recombinant Mouse IGFBP-1 (Catalog # 1588-B1) and Recombinant Human IGFBP-5 (Catalog # 875-B5). PVDF Membrane was probed with 1 µg/mL of Mouse Anti-Human IGFBP-1 Monoclonal Antibody (Catalog # MAB675) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for IGFBP-1 at approximately 26 kDa (as indicated). This experiment was conducted under non-reducing conditions and using Immunoblot Buffer Group 3.

Recombinant Human IGFBP‑1 (Catalog # 871-B1) inhibits Recombinant Human IGF‑I (Catalog # 291-G1) induced proliferation in the MCF‑7 human breast cancer cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IGF‑I (6 ng/mL) activity elicited by Recombinant Human IGFBP‑1 (5 µg/mL) is neutralized (green line) by increasing concentrations of Human IGFBP‑1 Monoclonal Antibody (Catalog # MAB675). The ND50 is typically 10-40 µg/mL.

Differentiation-dependent protein expression of PRL and IGFBP1 in culture supernatants of HDSC and THESC. Cells were stimulated in the absence or presence of cAMP and/or E2P4 for 3, 6, 9 and 12 days. Supernatants were collected and PRL and IGFBP1 protein concentrations were measured by ELISA and Western blotting, respectively. Normalization of protein concentrations, ELISA, and immunodetection of IGFBP1 on membranes were performed as mentioned in Materials and Methods. A) ELISA of PRL in HDSC and THESC. Data represent mean values ± SEM of three experiments performed in duplicates. * indicates p < 0.05 compared to negative control (n.c.) of the same day; n.s., not significant; # indicates p < 0.05 between cAMP-treated and cAMP/E2P4-stimulated cultures. PRL expression in controls and E2P4-treated THESC were below the detection limit and therefore omitted from the graph. B) Western blot showing IGFBP1 (32 kD) expression in HDSC and THESC. Marker bands (kD) are depicted on the left side. Representative examples are shown. Image collected and cropped by CiteAb from the following publication (//rbej.biomedcentral.com/articles/10.1186/1477-7827-9-155), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: WB, B/N, ELISA(Cap)
• Clone: 33627
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

IGFBP-1 Antibody (33627) [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human IGFBP-1
• Specificity: Detects human IGFBP-1 in ELISAs and Western blots. In Western blots, detection of recombinant mouse IGFBP-1 is observed but no cross‑reactivity with recombinant human (rh) IGFBP‑2, rhIGFBP‑3, rhIGFBP‑4 or rhIGFBP-5 is observed.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: IGFBP1
• Purity Statement: Protein A or G purified from ascites
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Neutralization 10-40 ug/mL
  • Western Blot 1 ug/mL
• Application Notes: ELISA Detection: Human IGFBP-1 Biotinylated Antibody (Catalog number BAF871)
  Standard: Recombinant Human IGFBP-1 (Catalog number 871-B1)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
  *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IGFBP-1 Antibody (33627) [Unconjugated]

• alpha-pregnancy-associated endometrial globulin
• amniotic fluid binding protein
• binding protein-25
• binding protein-26
• binding protein-28
• growth hormone independent-binding protein
• hIGFBP-1
• IBP1
• IBP-1
• IGF-binding protein 1
• IGFBP1
• IGFBP-1
• IGF-BP25
• insulin-like growth factor binding protein 1
• insulin-like growth factor-binding protein 1
• Placental protein 12
• PP12AFBP

Background

The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-transitional modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Human IGFBP-1 cDNA encodes a 259 amino acid (aa) residue precursor protein with a putative 25 aa residue signal peptide that is processed to generate the 234 aa residue mature protein. IGFBP-1 contains an integrin receptor recognition sequence (RGD sequence) but lacks potential N-linked glycosylation sites. IGFBP-1 is expressed in liver, decidua, kidneys and is the most abundant IGFBP in amniotic fluid. Serum levels of IGFBP-1 are lowest after meals. Hepatocyte production of IGFBP-1 is regulated at the transcriptional level due to the affects of insulin and corticosteriods. IGFBP-1 binds equally well to IGF-I and IGF-II, with phosphorylated forms of IGFBP-1 exhibiting higher binding affinities.

1. Jones, J.I. and D.R. Clemmons (1995) Endocrine Rev. 16:3.
2. Kelley, K.M. et al. (1996) Int. J. Biochem. Cell Biol. 28:619.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IGFBP-1 Antibody (MAB675)(6)

Publications using MAB675

• X Li, N Niu, J Sun, Y Mou, X He, L Mei IL35 predicts prognosis in gastric cancer and is associated with angiogenesis by altering TIMP1, PAI1, and IGFBP1 FEBS Open Bio, 2020-11-09;0(0):. 2020-11-09 [PMID: 33064893] (Neutralization, Human)
• Nijaguna M, Patil V, Urbach S, Shwetha S, Sravani K, Hegde A, Chandramouli B, Arivazhagan A, Marin P, Santosh V, Somasundaram K Glioblastoma-derived Macrophage Colony-stimulating Factor (MCSF) Induces Microglial Release of Insulin-like Growth Factor-binding Protein 1 (IGFBP1) to Promote Angiogenesis. J Biol Chem, 2015-08-05;290(38):23401-15. 2015-08-05 [PMID: 26245897] (Neutralization, Human)
• Saleh L, Otti GR, Fiala C, Pollheimer J, Knofler M Evaluation of human first trimester decidual and telomerase-transformed endometrial stromal cells as model systems of in vitro decidualization. Reprod. Biol. Endocrinol., 2011-12-07;9(0):155. 2011-12-07 [PMID: 22151839] (Western Blot, Human)
• Hu H, Kwun J, Aizenstein BD, Knechtle SJ Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation, 2009-06-27;87(12):1814-20. 2009-06-27 [PMID: 19543058] (Antibody Array Development, Human)
• Borai A, Livingstone C, Mehta S, Zarif H, Abdelaal F, Ferns G Biological variation in fasting serum insulin-like growth factor binding protein-1 (IGFBP-1) among individuals with a varying glucose tolerance. Clin. Biochem., 2009-05-20;0(0):. 2009-05-20 [PMID: 19463807] (ELISA Development, Western Blot, Human)
• Nakamura M, Miyamoto S, Maeda H, Ishii G, Hasebe T, Chiba T, Asaka M, Ochiai A Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. Biochem. Biophys. Res. Commun., 2005-08-05;333(3):1011-6. 2005-08-05 [PMID: 15964556] (Western Blot, Human)

Bioinformatics

• Gene Symbol: IGFBP1